PROCTER & GAMBLE HEALTH | ALKEM LABORATORIES | PROCTER & GAMBLE HEALTH/ ALKEM LABORATORIES |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 34.6 | 37.2 | 93.0% | View Chart |
P/BV | x | 10.6 | 6.5 | 162.9% | View Chart |
Dividend Yield | % | 2.0 | 1.0 | 197.1% |
PROCTER & GAMBLE HEALTH ALKEM LABORATORIES |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
PROCTER & GAMBLE HEALTH Jun-23 |
ALKEM LABORATORIES Mar-23 |
PROCTER & GAMBLE HEALTH/ ALKEM LABORATORIES |
5-Yr Chart Click to enlarge
|
||
High | Rs | 5,366 | 3,625 | 148.0% | |
Low | Rs | 3,883 | 2,835 | 137.0% | |
Sales per share (Unadj.) | Rs | 740.7 | 970.1 | 76.4% | |
Earnings per share (Unadj.) | Rs | 138.2 | 84.2 | 164.2% | |
Cash flow per share (Unadj.) | Rs | 155.2 | 110.2 | 140.8% | |
Dividends per share (Unadj.) | Rs | 95.00 | 50.00 | 190.0% | |
Avg Dividend yield | % | 2.1 | 1.5 | 132.7% | |
Book value per share (Unadj.) | Rs | 447.6 | 756.4 | 59.2% | |
Shares outstanding (eoy) | m | 16.60 | 119.57 | 13.9% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 6.2 | 3.3 | 187.5% | |
Avg P/E ratio | x | 33.5 | 38.4 | 87.2% | |
P/CF ratio (eoy) | x | 29.8 | 29.3 | 101.6% | |
Price / Book Value ratio | x | 10.3 | 4.3 | 241.9% | |
Dividend payout | % | 68.7 | 59.4 | 115.7% | |
Avg Mkt Cap | Rs m | 76,761 | 386,207 | 19.9% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 2,062 | 21,314 | 9.7% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 12,296 | 115,993 | 10.6% | |
Other income | Rs m | 184 | 2,161 | 8.5% | |
Total revenues | Rs m | 12,480 | 118,153 | 10.6% | |
Gross profit | Rs m | 3,247 | 15,065 | 21.6% | |
Depreciation | Rs m | 281 | 3,104 | 9.1% | |
Interest | Rs m | 8 | 1,074 | 0.7% | |
Profit before tax | Rs m | 3,142 | 13,048 | 24.1% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 847 | 2,980 | 28.4% | |
Profit after tax | Rs m | 2,295 | 10,068 | 22.8% | |
Gross profit margin | % | 26.4 | 13.0 | 203.3% | |
Effective tax rate | % | 27.0 | 22.8 | 118.1% | |
Net profit margin | % | 18.7 | 8.7 | 215.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,713 | 86,064 | 13.6% | |
Current liabilities | Rs m | 6,791 | 37,071 | 18.3% | |
Net working cap to sales | % | 40.0 | 42.2 | 94.8% | |
Current ratio | x | 1.7 | 2.3 | 74.3% | |
Inventory Days | Days | 263 | 33 | 806.4% | |
Debtors Days | Days | 343 | 67 | 511.9% | |
Net fixed assets | Rs m | 10,617 | 37,245 | 28.5% | |
Share capital | Rs m | 166 | 239 | 69.4% | |
"Free" reserves | Rs m | 7,265 | 90,208 | 8.1% | |
Net worth | Rs m | 7,431 | 90,447 | 8.2% | |
Long term debt | Rs m | 0 | 0 | - | |
Total assets | Rs m | 22,330 | 124,541 | 17.9% | |
Interest coverage | x | 409.1 | 13.2 | 3,109.9% | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 0.6 | 0.9 | 59.1% | |
Return on assets | % | 10.3 | 8.9 | 115.3% | |
Return on equity | % | 30.9 | 11.1 | 277.4% | |
Return on capital | % | 42.4 | 15.6 | 271.5% | |
Exports to sales | % | 0 | 14.6 | 0.0% | |
Imports to sales | % | 13.1 | 0 | - | |
Exports (fob) | Rs m | NA | 16,916 | 0.0% | |
Imports (cif) | Rs m | 1,605 | NA | - | |
Fx inflow | Rs m | 1,465 | 16,916 | 8.7% | |
Fx outflow | Rs m | 1,605 | 4,190 | 38.3% | |
Net fx | Rs m | -140 | 12,727 | -1.1% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,360 | 16,825 | 14.0% | |
From Investments | Rs m | -215 | 1,128 | -19.1% | |
From Financial Activity | Rs m | -985 | -17,608 | 5.6% | |
Net Cashflow | Rs m | 1,160 | 416 | 278.8% |
Indian Promoters | % | 0.0 | 56.7 | - | |
Foreign collaborators | % | 51.8 | 0.0 | - | |
Indian inst/Mut Fund | % | 20.0 | 24.7 | 80.7% | |
FIIs | % | 6.2 | 9.1 | 68.5% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 48.2 | 43.3 | 111.4% | |
Shareholders | 56,778 | 65,830 | 86.2% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare PROCTER & GAMBLE HEALTH With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | Procter & Gamble Health | ALKEM LABORATORIES | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -0.43% | 0.90% | 0.45% |
1-Month | -1.15% | -2.01% | 2.55% |
1-Year | 0.73% | 43.03% | 56.14% |
3-Year CAGR | -8.76% | 20.57% | 15.22% |
5-Year CAGR | 4.97% | 23.40% | 19.63% |
* Compound Annual Growth Rate
Here are more details on the Procter & Gamble Health share price and the ALKEM LABORATORIES share price.
Moving on to shareholding structures...
The promoters of Procter & Gamble Health hold a 51.8% stake in the company. In case of ALKEM LABORATORIES the stake stands at 56.7%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of Procter & Gamble Health and the shareholding pattern of ALKEM LABORATORIES.
Finally, a word on dividends...
In the most recent financial year, Procter & Gamble Health paid a dividend of Rs 95.0 per share. This amounted to a Dividend Payout ratio of 68.7%.
ALKEM LABORATORIES paid Rs 50.0, and its dividend payout ratio stood at 59.4%.
You may visit here to review the dividend history of Procter & Gamble Health, and the dividend history of ALKEM LABORATORIES.
For a sector overview, read our pharmaceuticals sector report.
After opening the day on high, Indian share markets reversed the trend as the session progressed and ended the lower.